New Antibiotic for MRSA Infections is Ready for US Clinical Trials
Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections.
Originally published on 26/02/2018
Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application.
Destiny Pharma wants to combat the growing antibiotic resistance crisis by targeting post-surgical infections of methicillin-resistant Staphylococcus aureus (MRSA). The FDA has accepted an investigational new drug application (IND) for Destiny’s MRSA candidate, XF-73, which will allow the company to complete Phase I and finalize the design of a Phase II trial.
XF-73 is a dicationic porphyrin molecule, which is a member of a new class of antibiotics called XF drugs. Interestingly, XF-73 is a nasal gel to reduce the entry of S.aureus through the nose, which represents the source of around a third of all post-surgical infections. The candidate has demonstrated a number of major advantages over current drugs, including their capacity to kill bacteria even when they’re not actively growing; and to attack bacteria within biofilms, a structure that normally protects them from antibiotics.
Destiny launched a £15.3M (€16.7M) IPO on the London Stock Exchange’s AIM market in September and the company’s stock price is up by over 3% this morning. Another company working on new antibiotics is Motif Bio, which is hoping to bring its candidate, Iclaprim, to market after it achieved positive Phase III results.
Image via royaltystockphoto.com / Shutterstock
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.